Breast Cancer is considering the most common cancer in Iraq and the major cause of cancer related deaths among women Iraqi Cancer Registry and Ministry of Health, Republic of Iraq, and also Among women in Iraq, breast cancer is the most frequent type of cancer. Material AND Methods: This study was designed to focus on microRNAs expression in breast cancer, by Measuring the levels of circulating microRNAs in all samples by determining the fold expression of the detected microRNAs by RT qPCR. The study, involved 49 specimens were collected from the point of view of patients, particularly women with breast cancer, and blood samples were fully taken, in addition to taking samples in the same way as combining those healthy women (control group) 40 samples, and the work of extracting the RNA in the method of extracting the organic Chloroform of samples of the full blood of all samples in EDTA tubes. The study includes take information’s patient (age, city, history, and to adding information from histopathology examination). The results were referred to increase in gene expression to miRNA Iet-7 family (type b) in patient samples (BC females) compared with control group (healthy women) by q-RT-PCR also measured IL-8 levels by ELISA technique and the results were referred to raise in IL-8 levels of BC females for serum samples compared with control group (healthy women). The cut off value for miR-let-7 was > 11.18-fold change with low sensitivity (58.5 %), high specificity (97.5 %) and good accuracy (81.8 %). Therefore, can be used MiRNA Let-7 as biomarker predictors of diagnosis of breast cancer. Conclusion: The current study was concluded, significant over productions of all investigated parameters referred to increase in levels micro-RNA let-7 family (let-7 type-b) seems to have potential role in breast prognosis of cancer progression when compared with healthy people. This study has found that all the investigated parameters were associated with moderate to high grade carcinoma.
Almost one-third of all female malignancies recorded in Iraq's most recent Iraqi Cancer Registry are breast cancers, making it the most common kind among women. With an anticipated 9.6 million deaths due to cancer in 2018, it is the second largest cause of death worldwide. One out of every six people who die in the world does so as a result of cancer. In low- and middle-income nations, cancer kills more than 70 percent of the population. Methods: This study include 49 samples patients and 40 samples (control group) which collection by draw of blood by gel tube and also the specimens were used centrifuge to get serum to measuring the interlukein-8 level by ELISA technique to both groups (patients, control). Results: measured IL-8 levels by ELISA technique and the results were referred to raise in IL-8 levels of BC females for serum samples compared with control group (healthy women). The cutoff value of serum IL-8 was >26.73 with good sensitivity, specificity and accuracy level respectively (73.47 %, 75 % and 72.0 %). The serum level of IL-8 was significantly higher in breast cancer group in comparison with control group, 36.69 (27.39) fold change versus 20.55 (13.83) fold change, respectively (p < 0.001). Conclusion: This study has found that the investigated interlukein-8 levels were associated with moderate to high grade carcinoma, this study may clarify that IL-8 along very important predictive and diagnostic marker for breast cancer and treatment responsiveness.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.